Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX3397 + Pembrolizumab in Advanced Solid Tumors
NCT02452424Phase 2Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2015
- Primary completion
- Aug 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of pexidartinib in melanoma, non-small cell lung cancer (NSCLC), ovarian cancer and 2 more (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Treatment-emergent Adverse Events at 2 years. Started Jul 2015; status: terminated.
02
Drugs
pexidartinib
03
Conditions
melanomanon-small cell lung cancer (NSCLC)ovarian cancergastrointestinal stromal tumor (GIST)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02452424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452424.